|
|
Blood, 1 May 2007, Vol. 109, No. 9, pp. 3786-3793.
Prepublished online as a Blood First Edition Paper on January 9, 2007; DOI 10.1182/blood-2006-06-030023.
Previous Article | Table of Contents | Next Article 
IMMUNOBIOLOGY
FcRL6, a new ITIM-bearing receptor on cytolytic cells, is broadly expressed by lymphocytes following HIV-1 infection
Timothy J. Wilson1,
Rachel M. Presti1,2,
Ilaria Tassi1,
Edgar T. Overton2,
Marina Cella1, and
Marco Colonna1
1 Department of Pathology and Immunology and
2 Division of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St Louis, MO
Fc receptorlike proteins (FcRLs) are a growing family of molecules homologous to Fc RI. Whereas all 7 previously reported Fc receptor homologs are expressed by B cells, here we report a new receptor, FcRL6, that is expressed by cytolytic cells including natural killer (NK) cells and effector and effector-memory CD8+ T cells. FcRL6 contains a novel cytoplasmic cysteine-rich motif and recruits SHP-2 through a phosphorylated ITIM, indicating a potential signaling function in effector lymphocytes. In vitro, FcRL6 does not greatly influence NK-cell or CD8+ T-cellmediated cytotoxicity and has minimal impact on cytokine secretion. However, FcRL6 expression among T lymphocytes is greatly expanded in human immunodeficiency virus type 1 (HIV-1)infected individuals, and includes not only effector and effector-memory CD8+ T cells but also populations of CD4+ T cells. Expansion of FcRL6-positive lymphocytes is not related to viral load, but is indicative of the dysregulated expansion of terminally differentiated effector lymphocyte populations in response to chronic HIV-1 infection and may serve as an important marker for chronic immune activation and for tracking the generation of effector cells following immune stimulation.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
A. Iannello, O. Debbeche, S. Samarani, and A. Ahmad
Antiviral NK cell responses in HIV infection: II. viral strategies for evasion and lessons for immunotherapy and vaccination
J. Leukoc. Biol.,
July 1, 2008;
84(1):
27 - 49.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|